Skip to content

Cardiac Magnetic Resonance Utilities in the Evaluation of Ischemic Heart Disease

CARDIAC MAGNETIC RESONANCE UTILITIES IN THE EVALUATION OF ISCHEMIC HEART DISEASE: Topographical Correlation Between Ischemic Territory Injury and Coronary Angiography

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01397357
Acronym
CARDIO-RM
Enrollment
146
Registered
2011-07-19
Start date
2011-07-31
Completion date
2015-03-31
Last updated
2016-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Ischemia

Keywords

Cardiac magnetic resonance, Myocardial Ischemia, Coronary Artery Disease, suspected Myocardial Ischemia

Brief summary

The purpose of this study is to evaluate CARDIAC MAGNETIC RESONANCE UTILITIES IN THE ISCHEMIC HEART DISEASE as topographical correlation between ischemic territory injury and coronary angiography.

Detailed description

Assessing the accuracy of Cardio-RM identifying ischemic territories and their correspondence to the presence of critical coronary lesions, comparing the presence, extent and regional inducible ischaemia in the Cardiac-MRI with the presence and characteristics of vascular lesions in coronary angiography. In particular, the study aims to evaluate the correlation between topography and function of the ischemic area revealed by the resonance and coronary artery disease documented coronary angiography.

Interventions

OTHERCardiac magnetic resonance - CINE MRI stress test.

Cardiac magnetic resonance - dipyridamole or dobutamine MRI stress test.

Sponsors

Ettore Sansavini Health Science Foundation
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. patients with suspected ischemic heart disease or recurrent Myocardial ischemic symptoms defined as: * presence of: * chest pain related to the effort lasting 5-20 minutes, and / or * positive stress test for inducible Myocardial ischemia * presence of at least one of the following risk factors: smoke family history of cardiovascular disease hypertension dyslipidemia diabetes mellitus NID / ID 2. no contraindications to perform coronary angiography 3. informed written consent to the processing of personal and sensible data, signed and dated by the patient.

Exclusion criteria

* Unstable angina; * Severe aortic stenosis * Hypertrophic cardiomyopathy * Pacemaker and \\ or defibrillator * Coronary stent implantation in 90 days before Cardiac MRI * Intracranial metal clips * Severe hypertension (systolic blood pressure\> 240 mmHg, and diastolic blood pressure above 120 mmHg) * Ventricular thrombosis and \\ or atrial * Aortic aneurysm and \\ or aortic dissection * Myocarditis, endocarditis, pericarditis * Critical stenosis of the left notes * State of severe anxiety or claustrophobia * Contraindications to the use of atropine (BAV advanced glaucoma, pyloric stenosis, prostatic hypertrophy)

Design outcomes

Primary

MeasureTime frameDescription
Accuracy of Cardio-RM identifying ischemic territories1 monthAssessing the accuracy of Cardio-RM identifying ischemic territories and their correspondence to the presence of critical coronary lesions, comparing the presence, extent and regional inducible ischaemia in the Cardiac-MRI with the presence and characteristics of vascular lesions in coronary angiography.

Secondary

MeasureTime frameDescription
correlation between resonance and coronary artery disease documented coronary angiography.1 monthcomparison of diagnostic positivity for inducible ischemia assessed by Cardiac-MRI and the presence of coronary lesions of various degrees evaluated by coronary angiography
topographic correlation between ischemic territory and coronary lesions1 monthtopographic correlation between ischemic territory assessed by Cardiac-MRI and coronary lesions evaluated by coronary angiography, using the criteria defined in Sintax study and BARI study.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026